Risk begins with the consequence of a wrong result
The company operates a distributed healthcare service in which quality, identity, sample or information integrity and timely communication are central to trust. The Risk Chair must help the Board understand how a failure travels: from collection or intake through transport, processing, interpretation, reporting, clinician or customer action, complaint and correction. The role also participates in Audit and NRC, allowing risk evidence to influence controls and leadership.
Quality and clinical governance
The committee will examine pre-analytical, analytical and post-analytical error; method and equipment validation; proficiency testing; calibration; result amendment; critical-value communication; referral arrangements; complaint; and corrective-action effectiveness. Network averages should not conceal site, shift, instrument or partner variation.
The Board should know which errors can cause serious harm even when occurrence is rare. Near misses, repeat events and failure to communicate deserve consequence-based escalation. Quality metrics must be supported by reliable definitions and independent assurance.
Data and cyber responsibility
Patient or customer identity, orders, results and histories require governance over access, matching, interfaces, consent, retention, sharing and correction. The Chair will ask how a person discovers and remedies an error and whether corrected information reaches all recipients who relied on it.
Cyber resilience should prioritise continuity and safety. Recovery tests must include critical reports, identity services, instrument interfaces, third parties, communication and safe manual procedures. Restoration that recovers data but cannot establish its integrity is incomplete.
Network and partner risk
Owned sites, collection points, logistics and referral partners create a single customer promise with uneven control boundaries. Material partners will be assessed for capability, training, quality, data handling, continuity and audit access. Expansion proposals should show leadership capacity and quality-control maturity, not only demand and unit economics.
Audit and NRC interface
The Audit Committee will consider revenue, receivables, provisioning, acquisition accounting, capex, inventory or consumables, fraud, related parties and IT controls through the operating evidence. NRC will review succession for clinical/technical, quality, technology, finance and operating leadership and whether incentives reward accuracy, escalation and service as well as volume.
First 120 days
The Chair will select one high-consequence service journey and lead a Board-level failure-mode review. Management will demonstrate prevention, detection, communication, remedy and recovery. The result will determine which indicators belong on the Risk dashboard and which scenarios require rehearsal.
External communication is part of the control environment. A quality or data event may require communication with customers, clinicians, partners, regulators and investors at different times and levels of detail. The Chair will test whether facts are verified, uncertainty is stated honestly, corrective instructions are usable and updates continue until affected decisions can be made safely.
Candidate profile
Relevant backgrounds include healthcare CEOs, clinical or laboratory leaders with enterprise governance experience, quality/regulatory executives, CIO/CISOs in health, CROs and audit leaders. Candidates must understand the boundary between governance and clinical management. Prior Risk Committee service is preferred. DIN, independence and databank compliance are required, together with availability for site exposure and material quality or data events.